Fourth, the interpretation of our results may be limited to a population with T2D under a healthcare system with universal health insurance coverage, where the co-pay of IAHI or LAIA would not be a serious concern for patients themselves in the clinical decision of selecting the type of basal insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.